CRESCENT BIOPHARMA, INC. Deferred Tax Liabilities, Gross
CRESCENT BIOPHARMA, INC. (CBIO) had Deferred Tax Liabilities, Gross of $387.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-26
- 2025-12-31: Deferred Tax Liabilities, Gross $387.00K.
- 2024-12-31: Deferred Tax Liabilities, Gross $0.00.
- 2023-12-31: Deferred Tax Liabilities, Gross $211.29K.
- 2022-12-31: Deferred Tax Liabilities, Gross $350.79K.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $387.00K 10-K · filed 2026-02-26 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2023-12-31 | $211.29K 10-K · filed 2025-02-13 |
| 2022-12-31 | $350.79K 10-K · filed 2024-03-27 |
| 2021-12-31 | $577.81K 10-K · filed 2023-03-29 |
| 2020-12-31 | $783.93K 10-K · filed 2022-03-03 |
| 2019-12-31 | $971.28K 10-K · filed 2021-03-02 |
| 2014-12-31 | $10.82K 10-K · filed 2016-02-29 |
| 2013-12-31 | $68.82K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |